68Ga-ZS2004

68Ga-ZS2004 is an investigational diagnostic radiopharmaceutical developed by the Chinese People's Liberation Army (PLA) General Hospital for use in positron emission tomography (PET) imaging. It consists of the ZS2004 ligand labeled with the positron-emitting radioisotope Gallium-68 (68Ga). The tracer specifically targets fibroblast activation protein alpha (FAP), a cell-surface glycoprotein that is highly overexpressed in cancer-associated fibroblasts (CAFs) within the tumor stroma of various solid tumors, including breast and prostate cancers. By binding to FAP, 68Ga-ZS2004 enables high-contrast imaging of the tumor microenvironment, potentially providing superior diagnostic accuracy and staging compared to conventional tracers like 18F-FDG, particularly in cancers with low glucose metabolism or high stromal content. It is currently being evaluated in clinical studies to assess its safety, biodistribution, and comparative efficacy against standard-of-care imaging agents like PSMA-targeted tracers and FDG.

Other names

Gallium Ga 68 ZS2004